

**MTN 014 - A Phase I Crossover Trial Evaluating the Pharmacokinetics of Tenofovir  
Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women  
Data as of July 14, 2015**

**Screen-out Summary**

	<b>Bronx - Lebanon</b>
Participants Screened	20
Participants Enrolled <sup>1</sup>	14 (70%)
Participants not Enrolled	6 (30%)
Participant did not return (refused or lost contact)	0 (0%)
Participant is eligible but declined enrollment	2 (10%)
Reason participant not enrolled is missing	0 (0%)
Participant not eligible <sup>2</sup>	4 (20%)
Participant < 18 years old	0 (0%)
Participant unable to provide adequate locator	0 (0%)
Participant not able or willing to provide informed	0 (0%)
Participant not male at birth	0 (0%)
Participant unavailable to return for all study visits,	0 (0%)
Participant not in general good health per IoR/designee	0 (0%)
Participant has not had consensual RAI in the last	0 (0%)
Participant unwilling to abstain from receptive/insertive	0 (0%)
Participant unwilling to abstain from participation	0 (0%)
PEP exposure in the 12 weeks prior to screening,	0 (0%)
Participant is HIV-positive	0 (0%)
Participant declines use of study-provided condoms	0 (0%)
Participant has symptoms suggestive of acute	0 (0%)
Participant use, anticipated use, or unwillingness	0 (0%)
Participant does not meet laboratory eligibility criteria	2 (50%)
Participant does not meet other clinical eligibility criteria	2 (50%)
Other reason, including investigator decision	0 (0%)

<sup>1</sup> Number of participants enrolled could differ from the accrual report since the data is taken from the ECI-1 CRF and not the ENR-1 CRF.

<sup>2</sup> Participants may be ineligible for more than one reason.

